Design and Execution of Sustainable Decentralized Clinical Trials

Author:

Singh Pritibha12ORCID,Burden Andrea M.23,Natanegara Fanni4,Beckman Robert A.5ORCID

Affiliation:

1. Novartis Pharma AG Basel Switzerland

2. Pharmacoepidemiology Group Institute of Pharmaceutical Sciences, ETH Zurich Zurich Switzerland

3. Leslie Dan Faculty of Pharmacy University of Toronto Toronto Ontario Canada

4. Eli Lilly and Company Indianapolis Indiana USA

5. Departments of Oncology and of Biostatistics, Bioinformatics, and Biomathematics, Lombardi Comprehensive Cancer Center and Innovation Center for Biomedical Informatics Georgetown University Medical Center Washington DC USA

Abstract

The decentralized clinical trial (DCT) approach is increasingly recognized as a means to accelerate the development of potential therapeutic interventions. DCTs have a crucial advantage over traditional clinical trials: patients are monitored in their environment using technology (e.g., wearables), that capture data as they continue in daily life. This narrative review outlines a gap analysis focused on the frameworks and guidance from expert working groups and regulatory agencies for the design and execution of DCTs. Eight DCT elements guided the analysis and summarized the frameworks and guidance: (1) suitability, (2) protocol, (3) investigational medicinal product (IMP) supply, (4) investigators and health care providers, (5) safety, (6) regulatory and ethics, (7) data and technology, and (8) engagement, communication, and advocacy. Based on the gap analysis, two key takeaways were identified: (1) a need for a comprehensive sustainability assessment of each DCT element; and (2) current frameworks and guidance provide recommendations on social sustainability and some on economic sustainability. DCTs are an essential evolution in healthcare research; however, more guidance related to a comprehensive assessment of designing and executing sustainable DCTs is needed. This is especially the case for environmental sustainability, including, for example, carbon footprint and disposal of IMPs and sensors.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference26 articles.

1. Decentralised, patient-centric, site-less, virtual, and digital clinical trials? From confusion to consensus

2. Opportunities and Challenges for Decentralized Clinical Trials: European Regulators’ Perspective

3. Burrows A.Decentralized and hybrid clinical trials report 2020.Inf. Connect (2020). Accessed July 16 2022.

4. The impact of decentralized and hybrid trials on sponsor and CRO collaborations;Diamond P.;Appl. Clin. Trials Online,2021

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3